An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
Public ClinicalTrials.gov record NCT02658890. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Study identification
- NCT ID
- NCT02658890
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 627 participants
Conditions and interventions
Conditions
Interventions
- BMS-986205 Drug
- Nivolumab Drug
- Ipilimumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 13, 2016
- Primary completion
- Oct 25, 2021
- Completion
- Oct 25, 2021
- Last update posted
- Aug 27, 2023
2016 – 2021
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0028 | Tucson | Arizona | 85724-5024 | — |
| Local Institution - 0026 | La Jolla | California | 92093-0698 | — |
| Local Institution - 0035 | Tampa | Florida | 33612-9497 | — |
| Local Institution - 0005 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0048 | Atlanta | Georgia | 30342 | — |
| Local Institution - 0027 | Chicago | Illinois | 60637 | — |
| Local Institution - 0051 | Lutherville | Maryland | 21093 | — |
| Local Institution - 0049 | Detroit | Michigan | 48201 | — |
| Local Institution - 0006 | St Louis | Missouri | 63110 | — |
| Local Institution - 0033 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0041 | New York | New York | 10016 | — |
| Local Institution - 0030 | Cleveland | Ohio | 44195 | — |
| Local Institution - 0034 | Philadelphia | Pennsylvania | 19111-2412 | — |
| Local Institution - 0057 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 0043 | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02658890, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2023 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02658890 live on ClinicalTrials.gov.